Difference between revisions of "Thalidomide (Thalomid)"
Jump to navigation
Jump to search
(Created page with "==General information== Class/mechanism: <ref name="insert">[http://www.thalomid.com/pdf/Thalomid%20PI%2072991-10.pdf Thalidomide (Thalomid) package insert]</ref><ref>[http://hem...") |
|||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: <ref name="insert">[http://www.thalomid.com/pdf/Thalomid%20PI%2072991-10.pdf Thalidomide (Thalomid) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/thalidomide.pdf Thalidomide (Thalomid) package insert (locally hosted backup)]</ref> | + | Class/mechanism: Immunomodulatory drug (IMiD); mechanism not fully understood. |
| − | <br>Route: | + | |
| − | <br>Extravasation: | + | Thalidomide's mechanism may involve immunomodulatory, antiinflammatory, and antiangiogenic effects and suppression of tumor necrosis factor-alpha (TNF-α) from peripheral blood mononuclear cells. Thalidomide has been observed to inhibit |
| + | angiogenesis in a human umbilical artery explant model in vitro.<ref name="insert">[http://www.thalomid.com/pdf/Thalomid%20PI%2072991-10.pdf Thalidomide (Thalomid) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/thalidomide.pdf Thalidomide (Thalomid) package insert (locally hosted backup)]</ref><ref>[http://www.thalomid.com Thalomid manufacturer's website]</ref> | ||
| + | <br>Route: PO | ||
| + | <br>Extravasation: n/a | ||
| + | *[http://www.thalomid.com/steps_program.aspx S.T.E.P.S. System for Thalidomide Education and Prescribing Safety]<ref>[http://www.thalomid.com/steps_program.aspx S.T.E.P.S. System for Thalidomide Education and Prescribing Safety]</ref> | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>. | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>. | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *[http://chemocare.com/bio/thalidomide. | + | *[http://www.thalomid.com/pdf/Thalomid%20PI%2072991-10.pdf#page=6 Thalidomide (Thalomid) package insert PDF pages 6-7]<ref name="insert"></ref> |
| + | *[http://chemocare.com/bio/thalidomide.asp Thalidomide (Thalomid) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/thalidomide.asp Thalidomide (Thalomid) patient drug information (Chemocare)]</ref> | ||
*[http://www.uptodate.com/contents/thalidomide-patient-drug-information Thalidomide (Thalomid) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/thalidomide-patient-drug-information Thalidomide (Thalomid) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/thalidomide-patient-drug-information Thalidomide (Thalomid) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/thalidomide-patient-drug-information Thalidomide (Thalomid) patient drug information (UpToDate)]</ref> | ||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 23:55, 24 February 2012
General information
Class/mechanism: Immunomodulatory drug (IMiD); mechanism not fully understood.
Thalidomide's mechanism may involve immunomodulatory, antiinflammatory, and antiangiogenic effects and suppression of tumor necrosis factor-alpha (TNF-α) from peripheral blood mononuclear cells. Thalidomide has been observed to inhibit
angiogenesis in a human umbilical artery explant model in vitro.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert[1].
Patient drug information
- Thalidomide (Thalomid) package insert PDF pages 6-7[1]
- Thalidomide (Thalomid) patient drug information (Chemocare)[5]
- Thalidomide (Thalomid) patient drug information (UpToDate)[6]
References
- ↑ 1.0 1.1 1.2 Thalidomide (Thalomid) package insert
- ↑ Thalidomide (Thalomid) package insert (locally hosted backup)
- ↑ Thalomid manufacturer's website
- ↑ S.T.E.P.S. System for Thalidomide Education and Prescribing Safety
- ↑ Thalidomide (Thalomid) patient drug information (Chemocare)
- ↑ Thalidomide (Thalomid) patient drug information (UpToDate)